A Concise Review on Current Omicron Variants and Subvariants (SARS-Cov-2) and Effective Vaccines against them
Journal of Pharmaceutical Research Science & Technology · 2022
DOI: 10.31531/jprst.1000167 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmaceutical Research Science & Technology, 2022. Verfasst von Mohammed Asadullah Jahangir.
Abstract (Originalsprache)
In late 2002 and early 2003, the SARS coronavirus and a new variant of the virus emerged in China and quickly spread around the globe. These viruses were easy to cultivate in tissue culture, which made it possible to study their genomic structure which were significantly different from human and animal coronavirus. The Covid-19 outbreak is a Group 2B Coronavirus. The genomic sequence of SARS-CoV-2 isolated from humans showed a similarity to SARS of 79.5%. The D614G mutation in the SARS-CoV-2 spikes was discovered at the beginning of March 2020. In the second wave of the SARS-COVID-2 epidemic in 2021, a number of novel COVID variants have been reported since the 2020 COVID outbreaks. The Omicron Variants, which were reported after the second wave in late 2021, is one of them. This concise review reports about Classification of new COVID-19 variants, Omicron variants and subvariants and their differences, and current vaccines in use against the newly mutated variants.
Zitieren
APA
Jahangir, M. A. (2022). A Concise Review on Current Omicron Variants and Subvariants (SARS-Cov-2) and Effective Vaccines against them. Journal of Pharmaceutical Research Science & Technology. https://doi.org/10.31531/jprst.1000167
Vancouver
Jahangir MA. A Concise Review on Current Omicron Variants and Subvariants (SARS-Cov-2) and Effective Vaccines against them. Journal of Pharmaceutical Research Science & Technology. 2022. doi:10.31531/jprst.1000167
BibTeX
@article{Jahangir2022,
author = {Jahangir, Mohammed Asadullah},
title = {A Concise Review on Current Omicron Variants and Subvariants (SARS-Cov-2) and Effective Vaccines against them},
journal = {Journal of Pharmaceutical Research Science & Technology},
year = {2022},
doi = {10.31531/jprst.1000167}
}
EUVIMED